Betaxolol (Systemic)
Kelas obat: Agen Antineoplastik
Panganggone Betaxolol (Systemic)
Hipertensi
Manajemen hipertensi (piyambak utawa kombinasi karo kelas agen antihipertensi liyane).
B-Blockers umume ora disenengi kanggo terapi hipertensi lini pertama miturut pedoman hipertensi adhedhasar bukti saiki, nanging bisa uga dianggep ing pasien sing duwe indikasi sing kuat (contone, MI sadurunge, penyakit jantung iskemik, gagal jantung) kanggo panggunaan utawa minangka terapi tambahan ing wong sing ora nanggapi kelas obat sing disenengi (inhibitor ACE, antagonis reseptor angiotensin II, blocker saluran kalsium, utawa diuretik thiazide). Pedoman hipertensi multidisiplin ACC/AHA 2017 nyatakake yen β-blocker sing digunakake kanggo penyakit jantung iskemik sing uga efektif kanggo ngedhunake BP kalebu Bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, propranolol, lan timolol.
Individualize pilihan therapy; nimbang karakteristik pasien (umpamane, umur, etnis / ras, komorbiditas, risiko kardiovaskular) uga faktor sing gegandhengan karo obat (umpamane, gampang administrasi, kasedhiyan, efek samping, biaya).
Pedoman hipertensi ACC/AHA 2017 nggolongake BP ing wong diwasa dadi 4 kategori: normal, dhuwur, hipertensi tahap 1, lan hipertensi tahap 2. (Deleng Tabel 1.)
Sumber: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Gugus Tugas Asosiasi Jantung babagan Pedoman Praktek Klinis. Hipertensi. 2018;71:e13-115.
Individu sing duwe SBP lan DBP ing 2 kategori beda (contone, SBP munggah pangkat lan DBP normal) kudu ditunjuk minangka kategori BP sing luwih dhuwur (yaiku, BP munggah pangkat).
Tabel 1. Klasifikasi ACC/AHA BP ing Dewasa1200Kategori
SBP (mm Hg)
DBP (mm Hg)
Normal
<120
lan
<80
Inggil
120–129
lan
<80
Hipertensi, Tahap 1
130–139
utawa
80–89
Hipertensi, Tahap 2
≥140
utawa
≥90
Tujuan manajemen hipertensi lan Nyegah yaiku kanggo nggayuh lan njaga kontrol BP sing optimal. Nanging, ambang BP digunakake kanggo nemtokake hipertensi, ambang BP paling luweh kanggo miwiti terapi obat antihipertensi, lan nilai BP target ideal tetep kontroversial.
Pedoman hipertensi ACC/AHA 2017 umume nyaranake target target BP (yaiku, BP kanggo digayuh kanthi terapi obat lan/utawa intervensi nonfarmakologi) <130/80 mm Hg ing kabeh wong diwasa tanpa preduli saka komorbiditas utawa tingkat risiko penyakit kardiovaskular aterosklerotik (ASCVD). Kajaba iku, target SBP <130 mm Hg umume dianjurake kanggo pasien ambulatory non-institusional ≥65 taun kanthi rata-rata SBP ≥130 mm Hg. Tujuan BP iki adhedhasar studi klinis sing nuduhake penurunan risiko kardiovaskular ing tingkat SBP sing luwih murah.
Pedoman hipertensi liyane umume duwe target target BP adhedhasar umur lan komorbiditas. Pedoman kayata sing ditanggepi dening panel ahli JNC 8 umume wis target target BP <140/90 mm Hg tanpa preduli saka risiko kardiovaskular lan nggunakake ambang BP sing luwih dhuwur lan target BP ing pasien tuwa dibandhingake karo sing disaranake dening ACC / AHA 2017. pedoman hipertensi.
Sawetara dokter terus ndhukung target BP sadurunge sing disaranake JNC 8 amarga kuwatir babagan kekurangan data umum saka sawetara uji klinis (contone, sinau SPRINT) sing digunakake kanggo ndhukung ACC/AHA 2017 pedoman hipertensi lan cilaka potensial (contone, efek obat sing saleh, biaya terapi) dibandhingake keuntungan saka BP ngedhunake pasien kanthi resiko penyakit kardiovaskular sing luwih murah.
Pirsani keuntungan potensial saka manajemen hipertensi lan biaya obat, efek sing ora becik, lan risiko sing ana gandhengane karo panggunaan macem-macem obat antihipertensi nalika nemtokake tujuan perawatan BP pasien.
Kanggo pancasan babagan kapan kudu miwiti terapi obat (ambang BP), pedoman hipertensi ACC/AHA 2017 nggabungake faktor risiko kardiovaskular sing ndasari. Penilaian risiko ASCVD dianjurake dening ACC/AHA kanggo kabeh wong diwasa kanthi hipertensi.
ACC/AHA saiki nyaranake miwiti terapi obat antihipertensi saliyane modifikasi gaya urip/perilaku ing SBP ≥140 mm Hg utawa DBP ≥90 mm Hg ing wong diwasa sing ora duwe riwayat penyakit kardiovaskuler (yaiku, pencegahan utama) lan risiko ASCVD sing kurang (resiko 10 taun <10%).
Kanggo pencegahan sekunder ing wong diwasa kanthi penyakit kardiovaskular sing dikenal utawa kanggo Nyegah utama ing risiko ASCVD luwih dhuwur (resiko 10 taun ≥10%), ACC/AHA nyaranake miwiti terapi obat antihipertensi kanthi rata-rata SBP ≥130 mm Hg utawa DBP rata-rata ≥80 mm Hg.
Wong diwasa kanthi hipertensi lan diabetes mellitus, penyakit ginjel kronis (CKD), utawa umur ≥65 taun dianggep duwe risiko dhuwur kanggo penyakit kardiovaskular; ACC / AHA nyatakake yen pasien kasebut kudu duwe terapi obat antihipertensi sing diwiwiti ing BP ≥130/80 mm Hg. Terapi obat individu ing pasien hipertensi lan faktor risiko kardiovaskular utawa liyane.
Ing hipertensi tahap 1, para ahli nyatakake yen cukup kanggo miwiti terapi obat kanthi nggunakake pendekatan perawatan langkah sing siji obat diwiwiti lan dititrasi lan obat liyane ditambahake kanthi urutan kanggo nggayuh target BP. Miwiti terapi antihipertensi kanthi 2 agen lini pertama saka kelas farmakologi sing beda-beda sing disaranake kanggo wong diwasa kanthi hipertensi tahap 2 lan rata-rata BP> 20/10 mm Hg ing ndhuwur target BP.
Pasien hipertensi ireng umume cenderung nanggapi luwih apik. monoterapi karo blocker saluran kalsium utawa diuretik thiazide tinimbang β-blocker. Nanging, respon suda kanggo β-blockers umume diilangi nalika diwenehake bebarengan karo diuretik thiazide.
Related obat
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
Carane nggunakake Betaxolol (Systemic)
Umum
Tujuan Pemantauan lan Perawatan BP
Administrasi
Administrasi Lisan
Administrasi lisan; panyerepan katon ora kena pengaruh pangan utawa alkohol.
Dosis
Kasedhiya minangka Betaxolol hydrochloride; dosis ditulis ing syarat-syarat uyah. Tablet sing kasedhiya sacara komersial ngemot 10 utawa 20 mg betaxolol hidroklorida, masing-masing ngemot 8,94 utawa 17,88 mg betaxolol.
Dewasa
Hipertensi OralKaping pisanan, 5-10 mg sapisan dina, mung siji utawa ing kombinasi karo diuretik. Dosis kaping pindho sawise 7-14 dina nganti 20 mg saben dina.
Rentang dosis biasa: Sawetara ahli nyatakake 5-20 mg sapisan dina.
Batesan Resep
Dewasa
Hipertensi OralMaksimum 40 mg saben dina.
Populasi Khusus
Gangguan Hepatik
Pengurangan dosis ora perlu sacara rutin. Gunakake kanthi ati-ati; ngawasi pasien kanthi ati-ati.
Gangguan Ginjal
Kaping pisanan, 5 mg sapisan saben dina ing wong sing ngalami gangguan abot utawa ngalami dialisis. Tambah dosis kanthi nambah 5 mg saben dina, ora luwih kerep tinimbang interval 2 minggu, nganti maksimal 20 mg saben dina.
Pasien Geriatrik
Kaping pisanan, 5 mg saben dina.
Penyakit Bronkospastik
Gunakake dosis sing paling murah (5-10 mg sapisan dina).
Yen dosis kudu ditambah, coba dibagi dosis saben dina. kanggo ngindhari konsentrasi plasma puncak sing luwih dhuwur sing digandhengake karo dosis sapisan dina.
Pènget
Kontraindikasi
Pènget/PanandhapPènget
Gagal Jantung
Kemungkinan presipitasi gagal jantung.
Aja nggunakake ing pasien sing gagal jantung dekompensasi; bisa digunakake kanthi ati-ati ing pasien kanthi fungsi miokardial sing ora nyukupi lan, yen perlu, ing pasien kanthi gagal jantung sing dikompensasi kanthi apik (umpamane, sing dikontrol karo glikosida jantung lan/utawa diuretik).
Pengobatan sing nyukupi (umpamane, karo glikosida jantung lan / utawa diuretik) lan pengamatan sing cedhak dianjurake yen ana pratandha utawa gejala gagal jantung sing bakal teka; yen gagal jantung terus, mungkasi terapi, mboko sithik yen bisa.
Penolakan Terapi kanthi cepetPembatalan terapi kanthi tiba-tiba ora dianjurake amarga bisa nambah gejala angina utawa precipitate MI ing pasien CAD.
Alon-alon nyuda dosis sajrone udakara 2 minggu lan ngawasi pasien kanthi ati-ati; menehi saran marang pasien supaya mbatesi aktivitas fisik kanggo sementara sajrone mundur saka terapi.
Yen ana eksaserbasi angina utawa insufisiensi koroner akut berkembang, bali terapi kanthi cepet lan miwiti langkah-langkah sing cocog kanggo ngatur angina pectoris sing ora stabil.
Penyakit bronkospastikKamungkinan bronkokonstriksi.
Umume ora bisa digunakake ing pasien sing nandhang penyakit bronkospastik, nanging bisa digunakake kanthi ati-ati ing pasien kasebut sing ora nanggapi utawa ora bisa ngidinke perawatan alternatif.
Atur dosis paling efektif (5-10 mg sapisan dina); bronkodilator (contone, agonis β2-adrenergik) kudu kasedhiya.
Bedah UtamaRisiko sing bisa digandhengake karo anestesi umum (umpamane, hipotensi abot, angel njaga denyut jantung) amarga nyuda kemampuan jantung kanggo nanggapi. kanggo stimulus β-adrenergik refleks. Gunakake kanthi ati-ati ing pasien sing ngalami operasi gedhe sing nglibatake anestesi umum; Anestesi sing digunakake ora bisa nyebabake depresi miokardial.
Diabetes lan HipoglikemiaMungkin nyuda tandha lan gejala hipoglikemia (umpamane, bisa nutupi tachycardia nanging ora kringet utawa pusing).
Gunakake kanthi ati-ati ing pasien. karo diabetes mellitus sing nampa obat hipoglikemik.
TirotoksikosisTandha-tandha hipertiroidisme (contone, takikardia) bisa ditutupi. Kemungkinan badai tiroid yen terapi tiba-tiba ditarik; ngawasi kanthi ati-ati pasien sing duwe utawa dicurigai ngalami tirotoksikosis.
Reaksi Sensitivitas
Reaksi AnafilaksisKamungkinan tambah reaktivitas kanggo bola-bali, ora sengaja, diagnostik, utawa tantangan terapeutik karo macem-macem alergen nalika njupuk agen β-blocking. Pasien kaya ngono bisa uga ora nanggapi dosis epinefrin sing biasa.
Tindakan Umum
Tekanan IntraokularMungkin nyuda tekanan intraokular. Bisa ngganggu tes skrining glaukoma; Penolakan terapi bisa nyebabake bali menyang tekanan intraokular. (Deleng Interaksi.)
Populasi Tertentu
KandhutanKategori C.
LaktasiDistribusi menyang susu. Gunakake kanthi ati-ati.
Panggunaan PediatrikKaamanan lan khasiat durung ditetepake.
Panggunaan GeriatrikKamungkinan tambah insiden bradikardia ing pasien> 65 taun dibandhingake karo wong diwasa sing luwih enom. Bradycardia (bisa uga ana hubungane karo dosis) bisa nanggapi pengurangan dosis. (Deleng Pasien Geriatrik ing Dosis lan Administrasi.)
Gangguan HepatikSanajan setengah umur eliminasi bisa saya tambah, reresik bisa tetep ora owah, nyebabake owah-owahan cilik ing AUC. (Deleng Gangguan Hepatik ing Dosis lan Administrasi.)
Gagal GinjalReresik bisa uga suda. Penyesuaian dosis bisa uga dibutuhake adhedhasar tingkat gangguan ginjel. (Deleng Gagal Ginjal ing Dosis lan Administrasi.)
Efek Samsaya Awon
Bradikardia, busung, sirah, pusing, lemes, lemes, insomnia, gugup, ngimpi aneh, impotensi, dyspnea, pharyngitis, rhinitis, infeksi saluran napas ndhuwur, dyspepsia, mual, diare, nyeri dada, artralgia, ruam.
Apa obatan liyane bakal mengaruhi Betaxolol (Systemic)
Obat Spesifik
Obat
Interaksi
Komentar
β-Blockers (solusi ophthalmic)
Kamungkinan efek aditif ing tekanan intraokular utawa β sistemik blokade
Agen pamblokiran saluran kalsium
Potensi hipotensi, gangguan konduksi AV, lan gagal ventrikel kiwa
Aja nggunakake bebarengan ing pasien kanthi gangguan fungsi jantung
Chlorthalidone
Interaksi farmakokinetik ora mungkin
Cimetidine
Interaksi farmakokinetik ora mungkin
Clonidine
Blockade β-adrenergik bisa nambah hipertensi rebound sawise mungkasi clonidine
Stop β -blocker sawetara dina sadurunge miwiti Penarikan bertahap saka clonidine
Yen ngganti clonidine, tundha wiwitan β-blocker kanggo sawetara dina sawise mungkasi clonidine
Hydrochlorothiazide
Farmakokinetik interaksi ora mungkin
Nifedipine
Interaksi farmakokinetik ora mungkin
Reserpine
Efek aditif
Monitor tandha-tandha hipotensi lan bradikardia (umpamane, vertigo, sinkop, hipotensi postural)
Warfarin
Ora ana potensiasi efek antikoagulan
Disclaimer
Kabeh upaya wis ditindakake kanggo mesthekake yen informasi sing diwenehake dening Drugslib.com akurat, nganti -tanggal, lan lengkap, nanging ora njamin kanggo efek sing. Informasi obat sing ana ing kene bisa uga sensitif wektu. Informasi Drugslib.com wis diklumpukake kanggo digunakake dening praktisi kesehatan lan konsumen ing Amerika Serikat lan mulane Drugslib.com ora njamin sing nggunakake njaba Amerika Serikat cocok, kajaba khusus dituduhake digunakake. Informasi obat Drugslib.com ora nyetujoni obat, diagnosa pasien utawa menehi rekomendasi terapi. Informasi obat Drugslib.com minangka sumber informasi sing dirancang kanggo mbantu praktisi kesehatan sing dilisensi kanggo ngrawat pasien lan / utawa nglayani konsumen sing ndeleng layanan iki minangka tambahan, lan dudu pengganti, keahlian, katrampilan, kawruh lan pertimbangan babagan perawatan kesehatan. praktisi.
Ora ana bebaya kanggo kombinasi obat utawa obat sing diwenehake kanthi cara apa wae kudu ditafsirake kanggo nuduhake yen obat utawa kombinasi obat kasebut aman, efektif utawa cocok kanggo pasien tartamtu. Drugslib.com ora nanggung tanggung jawab kanggo aspek kesehatan apa wae sing ditindakake kanthi bantuan informasi sing diwenehake Drugslib.com. Informasi sing ana ing kene ora dimaksudake kanggo nyakup kabeh panggunaan, pituduh, pancegahan, bebaya, interaksi obat, reaksi alergi, utawa efek samping. Yen sampeyan duwe pitakon babagan obat sing sampeyan gunakake, takon dhokter, perawat utawa apoteker.
Tembung kunci populer
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions